PRESS RELEASES

Parcom Capital acquires Viroclinics Biosciences

Parcom Capital has acquired the successful clinical research organisation Viroclinics Biosciences. Viroclinics believes Parcom is the perfect partner to help it realise its growth ambitions.

Viroclinics Biosciences endorsed for GLP compliancy

Viroclinics Biosciences serves as a virology contract research organization in the bio pharmaceutical community with preclinical, clinical diagnostic, assay development and clinical trial logistics services. Especially with extensive experience in clinical and...

ViroSpot MN assay, a novel tool for antigenic characterization of influenza viruses and serology

Selecting vaccine strains that match circulating influenza viruses antigenically remains an annual challenge. Vaccine mismatch [e.g., for recent A(H3N2) viruses] has contributed to reduced vaccine effectiveness. Reduced vaccine effectiveness not only may affect public health, but also causes economic losses due to absenteeism from work. Vaccine mismatches also fuel the ongoing debate about the effectiveness of the influenza vaccine.

Top floor for top company

On the 3rd of November 2016, Viroclinics Biosciences signed a rental agreement with its lessor Valad, for 825 m2 additional company space, located on the 21st floor of the Rotterdam Science Tower.

↓